Description: Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Home Page: www.outlooktherapeutics.com
Building F
Iselin,
NJ
08852
United States
Phone:
609 619 3990
Officers
| Name | Title |
|---|---|
| Mr. Ralph H. Thurman | Executive Chairman |
| Mr. Lawrence A. Kenyon CPA | EVP, CFO, Interim CEO, Treasurer, Secretary & Director |
| Mr. Jeffrey Evanson | Chief Commercial Officer |
| Mr. Joel Prieve | Senior Vice President of Licensing and M&A |
| Dr. Surendra Sharma M.D. | Senior Vice President of Medical Affairs |
| Dr. Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development & Regulatory Affairs |
| Mr. Jedd Comiskey | Senior VP - Head of Europe |
Exchange: STU
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 3.3333 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 10.8159 |
| Price-to-Sales TTM: | 10.3476 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 24 |